GM1 ganglioside-bound amyloid protein aggregate (GAβ)

GM1 ganglioside-bound amyloid protein aggregates, particularly GM1-bound Amyloid-beta (GAβ), are specialized protein-lipid complexes formed when amyloidogenic proteins interact with clusters of GM1 ganglioside in membrane lipid rafts [3, 4, 11]. These complexes act as potent endogenous seeds that catalytically accelerate the conversion of soluble, non-toxic monomers into toxic oligomers and fibrils, a process facilitated by the presence of cholesterol [6, 8, 9]. This membrane-mediated aggregation is considered a critical early event in the pathogenesis of neurodegenerative disorders like Alzheimer's and Parkinson's diseases [5, 11, 15]. Therapeutic strategies targeting these aggregates focus on preventing the initial protein-lipid interaction, disrupting the catalytic surface of the seed, or using specific antibodies to neutralize the toxic species [1, 5, 6]. By inhibiting the formation of these seeds, researchers aim to halt the progression of amyloid deposition and the resulting synaptic dysfunction and neurotoxicity [5, 16].

Other names

GM1-bound Amyloid-betaGAβGM1-AβMembrane-bound amyloid-betaGM1-mediated amyloid aggregate

Inhibition of amyloid protein binding to GM1 ganglioside clusters, competitive membrane binding, and neutralization of the catalytic seeding activity of membrane-bound aggregates.